Introduction
elevated during inflammation [3] . This acts on the one hand as a crucial causative factor in pathogenesis of anaemia of inflammation, by retention of heme-derived iron in the iron storage sites, thereby withholding it from the erythroid compartment [7] [8] [9] On the other hand, hepcidin suppression is observed in anemias, necessary to increase iron supply needed for the accelerated erythropoietic activity [10] . (Table 1) [11, 12] . Similarly, Ho-1 knock-out mice (Ho-1 KO mice) developed severe inflammation and anemia associated with low transferrin iron, and also hepatic and renal iron accumulation (Table 1) [13] . Therefore, it has been proposed that HO-1 facilitates iron efflux from hepatic and renal cells. Another in vitro study suggested a function for HO-1 in regulating cellular iron by inducing iron efflux [14] . Indeed, in 2000, the same group proposed the presence of an iron ATPase transporter that in association with HO-1 acts as an iron exporter [15] .
It has been reported that HO-1 deficiency in human exhibits both signs of inflammation and dysregulation of body iron homeostasis, such as iron accumulation in the kidneys and the liver
In the present study, we hypothesized that dysregulation of iron homeostasis present in 
Viability test

Cell viability after various treatments was monitored using a standard trypan blue exclusion test. In all experiments, both hepatoma and THP-1 cells were Ͼ95% viable after indicated treatments.
Quantitative polymerase chain reaction (Q-PCR)
Confluent hepatoma cells were treated for 6 hrs with different agents, including tin mesoporphyrin (SnMP, Frontier Scientific, UT, USA), cobalt protophorphyrin (CoPP, Frontier Scientific), hemin (Frontier Scientific) as the source of heme, and interleukin-6 (IL-6, R&D systems, Minneapolis, MN, USA)
. Two mmol/l stock solutions of SnMP, CoPP and hemin were freshly prepared as previously described [16] . Isolation of total RNA and subsequent cDNA synthesis were performed [17] [18] .
Flow cytometry
After treatment with HO-1 inducers, HO- 
HO-activity assay
Calcein assay for measurement of intracellular labile iron
A calcein assay was used to monitor intracellular labile iron accumulation as described elsewhere [19, 20] [19, 20] . Fe(III)ammoniumcitrate was used as a positive control to illustrate sensitivity of the assay.
HO-1-deficient patient and laboratory measurements
A patient with no functional HO-1 expression because of a two-nucleotide deletion within exon3 and a complete loss of exon2 of the HO-1 genes has been described previously [11, 12] . Informed consent was obtained and the study was approved by the Ethics Committee of Kanazawa University [11, 12] . The sera of the patient taken at two different time points exhibited low transferrin saturation, but elevated levels of ferritin and heme (Table 2) . Several laboratory parameters of the sera, as shown in Table 2 , were measured in previous studies [11, 12] , and remeasured in the present study. The two samples were taken 5 months apart when the patient was 6 years old. [22] . 
The boy died several months after the last blood sample was taken. Both samples were stored at Ϫ80ЊC. Remeasurement of laboratory parameters of the stored samples in the present study was carried out using routine laboratory methods [8] (Department of Clinical Chemistry, Radboud University Nijmegen Medical Centre, The Netherlands). Serum hepcidin was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) as described elsewhere
Statistical analysis
Results are expressed as means Ϯ standard errors of the means (S.E.).
Differences in quantitative measures were tested for significance using one-way ANOVA. All statistics were performed using the GraphPad Prism 4 statistical program (San Diego, CA, USA).
Results
HO-activity increases intracellular labile iron levels in THP-1 cells
Previous studies [13] [14] [15] 
Ferroportin induction by intracellular labile iron in human macrophage/monocyte-like cells
To examine whether HO-1 could directly regulate the iron exporter ferroportin, expression of ferroportin in THP-1 cells treated with
HO-activity modifying agents was analysed. This study was also aimed to examine direct involvement of HO-1 in cellular iron efflux as has been postulated [13] [14] [15] .
Increased HO-1 synthesis in THP-1 by heme ( Fig. 2A and B ) correlated with elevated expression of surface ferroportin (Fig. 3A-C) . Here, an incubation period of 24 hrs was chosen to allow stable surface expression of ferroportin on THP-1 cells. Addition of the specific HO-activity inhibitor SnMP [16, 26] did not affect heme-induced HO-1 expression (Fig. 2B) HO-induced ferroportin expression (Fig. 3B) (Fig. 2B) , did not stimulate ferroportin expression (Fig. 3B) . This is consistent with the absence of intracellular iron accumulation after CoPP stimulation (Fig. 1) . Thus, increased intracellular labile iron levels are necessary for induction of ferroportin expression. This was supported by our observation that iron chelator DF was able to counteract both heme-induced and iron-induced ferroportin expression (Fig. 3B) . DF appeared to also counteract the increased levels of intracellular labile iron (Fig. 1) .
In addition, we observed that ferroportin expression was induced by IL-6 (Fig. 3B) . Such induction of ferroportin by a proinflammatory cytokine has been previously reported [27] (Table 2) , hepcidin levels in the sera were expected to be increased. However, on the contrary, we found that hepcidin levels, in the two serum samples of the HO-1-deficient patient were very low (both values were Ͻ0.1 Mint/l, whereas normal range of fresh sera ϭ 0.6-9.9 Mint/l [22] , and normal range of stored sera ϭ 1.02-6.26 Mint/l, Table 2 ). These measured low levels of hepcidin in the stored patient sera are likely reflecting actual levels because (1) based on our methodology of hepcidin measurement, serum hepcidin preserves its stability even after several freezethaw cycles during storage [22] , (2) similarly, stored samples from healthy volunteers showed significantly higher levels of hepcidin, (3) additionally, values of both iron and serum parameters that had been measured previously in the fresh samples of the HO-1 patient [11] were similar as measured in the present study ( [16, 26] .
. This induction however is likely independent of HO-activity because SnMP did not counteract the effect of IL-6. Taken together, the results indicate that surface ferroportin expression is induced by intracellular labile iron. These data therefore suggest that the previously described HO-1-induced iron efflux [13-15] is likely mediated by a heme-derived iron-induced ferroportin expression.
Despite chronic inflammation and tissue iron loading in the HO-1-deficient patient there is lack of hepcidin synthesis
Because HO-1 deficiency results in tissue iron loading (Table 1) and chronic inflammation shown by enhanced levels of IL-6, CRP and haptoglobin (Table 2), we questioned whether HO-1 modulates the synthesis of liver hepcidin. We measured hepcidin levels using SELDI-TOF-MS in serum samples of the HO-1-deficient patient and from six healthy volunteers that were stored in Ϫ80ЊC for a similar time period and thus served as reference values (Table 2). Hepcidin levels from two serum samples of the patient from different periods of collection were measured to monitor the consistency of the values. Because of the presence of pathological chronic inflammation and tissue iron loading conditions, together with low transferrin saturation, but highly elevated ferritin levels
HO-1-activity was inducible in human hepatoma cells, and promoted intracellular labile iron accumulation
Because HO-1 deficiency exhibited hepcidin suppression, we questioned whether HO-1 could directly modulate HAMP expression in liver cells. We first tested whether HO-1-activity could be induced in human hepatoma cells, and promote intracellular labile iron accumulation. In HepG2 cells, treatment with 10 M heme for 6 hrs promoted substantial induction of HO-activity when compared to basal activity levels, whereas exposure to 10 M SnMP, completely abrogated HO-activity in these cells (data not shown). This confirms that in our in vitro systems, heme activated while SnMP inhibited HOactivity, as previously reported
In HepG2 and Hep3B cells (Fig. 4A) 
HO-1 does not modulate HAMP expression in human hepatoma cells
We next examined whether HO-1 could directly down-modulate HAMP expression in liver cells. To this end, we incubated HepG2 and Hep3B cells with HO-1 modulating agents, and measured HAMP transcript levels.
Incubation with the specific HO-activity inhibitor [16, 26] , SnMP, for 6 hrs modulated neither the amount of HO-1 nor HAMP transcripts (Table 3) 
. Likewise, prolonged incubation (i.e. 24 and 48 hrs, data not shown) did not affect transcript levels of both genes. CoPP increased HO-1 transcripts in both cell lines, however HAMP expression was not changed. Moreover, inhibition of HOactivity using SnMP in the presence of CoPP did not alter HAMP transcription (Table 3). These results indicate no direct modulatory effects of HO-1 levels and HO-activity on HAMP expression.
In the presence of IL-6, both HO-1 and HAMP transcripts were up-regulated (Table 3) . Because IL-6 could regulate both genes directly at transcriptional level [28] [29] [30] (Table 3 ). This effect may be attributed to increased levels of intracellular labile iron [31, 32] from heme degradation by HO-1 in hepatoma cells (Fig. 4) . Similarly, after iron treatment ( [1, 16, 37, 38] . HO-1 deficiency in vivo resulted in anaemia and hepatic and renal haemosiderosis [11, 16, [38] [39] [40] [41] . The deficiency also promotes severe chronic inflammation [11, 16, [38] [39] [40] [41] as shown by increased CRP, IL-6 and haptoglobin ( [42, 43] , inflammation [16, 37, 38] and haemolysis [11] . Similarly to the HO-1-deficient patient, accelerated hepatic iron loading has also been documented when Ho-1 KO mice were challenged with stress stimuli [39] [40] [41] (Fig. 5) . Indeed, extremely high sTfR levels were measured, confirming the presence of increased erythropoietic activity. In agreement with our findings, in mice models of hemolysis, iron loading and inflammation are sustained, whereas production of hepcidin is suppressed [44] . This is further corroborated in a rat model of hemolysis [45] . The patient's decreased serum hepcidin levels are thus likely to be the result of increased erythroid expansion that, by analogy with growth differentation factor-15 exclusively present in ␤-thalassaemia [35] through the systemic release of a thus far unknown factor, down-regulates hepatocyte hepcidin production. In addition, a down-regulatory effect of the anemia-associated tissue hypoxia on liver hepcidin expression may also contribute to the low hepcidin levels [46, 47] .
, the observed up-regulation is likely independent from each other. Furthermore, when HOactivity was inhibited, IL-6-induced HAMP expression was not affected. This further confirms the absence of direct modulatory effects of HO-activity on HAMP expression in hepatoma cells. In contrast, it was observed that upon HO-1 induction by heme, HAMP was slightly decreased, although this was not significant
We further investigated whether HO-1 could directly modulate ferroportin expression. Surface expression of ferroportin [5] (Fig. 5) .
During hemolysis, clearance of plasma heme and heme-containing proteins is carried out by the proximal tubular cells of the kidneys. This event is deleterious for the kidneys as exemplified by the extent of iron deposition in the proximal tubuli [11] and the tubular atrophia [12] [2] and the non-CO-forming pathways [50] , or from the oxidized free heme [51] .
Besides having defective macrophage iron recycling, HO-1 deficiency also exhibited hepatocyte iron loading in the liver (Table 1) [11, 12] . Similarly, Ho-1 KO mice show both hepatocyte and Kupffer iron overload [13] , whereas stress stimuli further induce iron loading exclusively in hepatocytes [39] . In this study, we have observed low hepcidin levels in the patient with HO-1 deficiency, which are similar to that of patients with juvenile forms of hereditary hemochromatosis [52] [53] [54] . These low concentrations of hepcidin may help explain the presence of hepatocyte iron loading [11, 12] 
